The government on Monday eased the restrictions on the export of injection Remdesivir and its active pharmaceutical ingredient. Their exports which were banned two months ago, have now been restricted and would require a license.
“The export of injection Remdesivir and its API… have been put under Restricted category with immediate effect. The export of Remdesivir Injection/API against the advance authorisation will not require a separate authorisation/permission”, the Directorate General of Foreign Trade (DGFT) said in a statement.
Under an advance licence, duty-free imports are bound to certain export obligations.
In April, the government had prohibited the exports of the anti-viral drug amid a surge in the Covid-19 cases in the country.
India has waived customs duty on the drug and its API till October 31 and also exempted from customs duty the import of beta cyclodextrin which is used in the manufacture of remdesivir. The duty on remdesivir was 10% earlier but total import levies would go up to 16.5% after integrated GST and a 1% social welfare surcharge. Beta cyclodextrin attracted a basic customs duty of 7.5%.